A newer version of this project is available. See below for other available versions.
Investigating the Prevalence of Gastrointestinal Symptomology Following Receipt of the COVID-19 Vaccine
Principal Investigator(s): View help for Principal Investigator(s) Kaly D Houston, Department of Research and Discovery, Stamford Hospital, Stamford, Connecticut, USA
Version: View help for Version V1
| Name | File Type | Size | Last Modified |
|---|---|---|---|
|
|
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet | 25.5 KB | 01/10/2023 12:37:PM |
Project Citation:
Houston, Kaly D. Investigating the Prevalence of Gastrointestinal Symptomology Following Receipt of the COVID-19 Vaccine. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2023-01-11. https://doi.org/10.3886/E183721V1
Project Description
Summary:
View help for Summary
The coronavirus disease of 2019 (COVID-19) pandemic presented novel and devastating conditions for both the general and high-risk populations. SARS-CoV-2 is known to affect the respiratory tract, however studies have reveals that changes in gastrointestinal (GI) symptomology are also a prevalent side effect. Although the COVID-19 vaccine has been able to alleviate some of the tumultuous circumstances, there is limited research on the lesser-known side effects experienced following receipt of the COVID-19 vaccination.
This study investigated the association between the COVID-19 vaccination and, when applicable, the contraction of acute COVID-19 infection, and resulting onset and/or changes in GI symptomology. The focus of the study was on both the general population and on those previously diagnosed with GI disorders, such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), the latter defined as a special needs population.
Through a short, anonymous survey, 215 participants were assessed for acute onset of GI issues and/or worsening of pre-existing GI issues following the receipt of one or more COVID-19 vaccine doses and, when it occurred, following contraction of a COVID-19 infection. Participants were requested to report demographic variables as well as descriptive statistics regarding side effects experienced post-COVID-19 vaccination and post-COVID-19 infection, when applicable. All analyses were performed using SAS version 9 and ANOVA was conducted for each survey item to assess for statistically significant differences between the groups, indicated by an omnibus p-value less than 0.05.
The resulting database demonstrates the prevalence of side effects following receipt of the COVID-19 vaccination to gain an understanding of how both the general and high-risk populations are being affected by the COVID-19 vaccine and booster doses.
This study investigated the association between the COVID-19 vaccination and, when applicable, the contraction of acute COVID-19 infection, and resulting onset and/or changes in GI symptomology. The focus of the study was on both the general population and on those previously diagnosed with GI disorders, such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), the latter defined as a special needs population.
Through a short, anonymous survey, 215 participants were assessed for acute onset of GI issues and/or worsening of pre-existing GI issues following the receipt of one or more COVID-19 vaccine doses and, when it occurred, following contraction of a COVID-19 infection. Participants were requested to report demographic variables as well as descriptive statistics regarding side effects experienced post-COVID-19 vaccination and post-COVID-19 infection, when applicable. All analyses were performed using SAS version 9 and ANOVA was conducted for each survey item to assess for statistically significant differences between the groups, indicated by an omnibus p-value less than 0.05.
The resulting database demonstrates the prevalence of side effects following receipt of the COVID-19 vaccination to gain an understanding of how both the general and high-risk populations are being affected by the COVID-19 vaccine and booster doses.
Scope of Project
Subject Terms:
View help for Subject Terms
COVID-19;
vaccine;
adverse reaction;
digestive symptoms;
functional gastrointestinal disorders
Geographic Coverage:
View help for Geographic Coverage
41° 3′ 10″ N, 73° 32′ 20″ W
Time Period(s):
View help for Time Period(s)
6/20/2022 – 6/18/2022
Collection Date(s):
View help for Collection Date(s)
6/20/2022 – 6/18/2022
Data Type(s):
View help for Data Type(s)
clinical data;
survey data
Methodology
Response Rate:
View help for Response Rate
Inclusion criteria: having received at least one COVID-19 vaccination
Exclusion criteria: not having received at least one COVID-19 vaccination
Exclusion criteria: not having received at least one COVID-19 vaccination
Sampling:
View help for Sampling
Convenience sampling to
collect de-identified survey
data from participants who had received at least one COVID-19 vaccination
Data Source:
View help for Data Source
SurveyMonkey de-identified data
Collection Mode(s):
View help for Collection Mode(s)
web-based survey
Related Publications
Published Versions
Report a Problem
Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.
This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.